A study involving 27 HCC patients who received ICB (a mix of anti-PD1/anti-PD-L1/anti-CTLA4 or combination) found Wnt-pathway mutation to be predictive of resistance to therapy [68]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.